Skip to content
← Holders

Kynam Capital Management, LP

What Kynam Capital Management, LP reported holding on Form 13F for the quarter ended Sep 30, 2026.

CIK 1907884 · Filed Nov 16, 2026

Positions
34
Reported value
$1.8B
Opened
4
Closed
2
Other managers included
0

Values are as the managers reported them, in dollars.Open the Form 13F on SEC EDGAR

Quarters on file

  1. Sep 30, 2025$1.3B
    35 positions
  2. Dec 31, 2025$1.6B
    37 positions
  3. Mar 31, 2026$1.6B
    39 positions
  4. Jun 30, 2026$1.8B
    32 positions
  5. Sep 30, 2026$1.8B
    34 positions
SecuritySharesChangeValueOf portfolio
LEGNLegend Biotech Corp
9.2M+205.0%$182.1M10.1%
CLDXCelldex Therapeutics, Inc.
5.1M−4.8%$164.2M9.1%
SNDXSyndax Pharmaceuticals Inc
8.2M+1.2%$153.2M8.5%
PCVXVaxcyte, Inc.
2.6M−10.8%$148.4M8.2%
VRDNViridian Therapeutics, Inc.
6.1M−4.7%$126.6M7%
COGTCogent Biosciences, Inc.
3.8M+3.4%$121.4M6.7%
TVTXTravere Therapeutics, Inc.
2M±0%$117.8M6.5%
URGNUroGen Pharma Ltd.
2.4M±0%$98.9M5.5%
VERAVera Therapeutics, Inc.
3M+3.8%$96.9M5.4%
BEAMBeam Therapeutics Inc.
3.9M+38.5%$96.2M5.3%
CTMXCytomX Therapeutics, Inc.
21.1M−2.6%$57.5M3.2%
MBXMBX Biosciences, Inc.
934.8K±0%$54.8M3%
SMMTSummit Therapeutics Inc.
3M+150.0%$50.7M2.8%
RLAYRelay Therapeutics, Inc.
2.8M−16.6%$49.7M2.7%
CGEMCullinan Therapeutics, Inc.
3.1M±0%$47.8M2.6%
IMCRImmunocore Holdings plc
1.4M±0%$41.6M2.3%
NRIXNurix Therapeutics, Inc.
1.2M±0%$28.3M1.6%
PHVSPharvaris N.V.
824.8K+24.6%$26.2M1.4%
BNRBurning Rock Biotech Ltd
1.2M±0%$21.8M1.2%
BCRXBiocryst Pharmaceuticals Inc
2.5M±0%$21M1.2%
SRZNSurrozen, Inc.
486.3KNew$15.6M0.9%
STROSutro Biopharma, Inc.
872.6K±0%$14.1M0.8%
XENEXenon Pharmaceuticals Inc.
280KNew$10.4M0.6%
EVMNEvommune, Inc.
1.2MNew$9.9M0.5%
PRLDPrelude Therapeutics Inc
2.3M−4.3%$9M0.5%
GERNGeron Corp
6.8M±0%$8.4M0.5%
PBLSParabilis Medicines, Inc.
250K±0%$8.1M0.4%
ALECAlector, Inc.
4.3M+13.1%$8M0.4%
AMRNAmarin Corp Plcuk
533K±0%$6.9M0.4%
HROWHarrow, Inc.
124.7KNew$3.8M0.2%
CRBUCaribou Biosciences, Inc.
2.5M±0%$3.2M0.2%
PRQRProQR Therapeutics N.V.
1.6M±0%$2.6M0.1%
ENGNenGene Therapeutics Inc.
457.9K±0%$915.7K0.1%
TRAWTraws Pharma, Inc.
84.4K±0%$50.1K0.1%